- ASCO: Seagen’s top-selling drug under threat as Bristol Myers’ Opdivo beats Adcetris in lymphoma FiercePharma
- Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma Medical Xpress
- ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer Yahoo Finance
- New Ovarian Cancer Drug Extends Survival in Resistant Disease Medpage Today
- Neoadjuvant Nivolumab and Chemotherapy Shows Continued Benefit in NSCLC Exploratory Analysis Targeted Oncology
- View Full Coverage on Google News
Read More: ASCO: Seagen’s top-selling drug under threat as Bristol Myers’ Opdivo beats